Drugs / AAA517
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05849298 Background | Jan 2024 → Dec 2026 expected | prostate neoplasm | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AAA517 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05849298 ↗ |
| Route | Intravenous | “Single intravenous dose of approx. 150 Megabecquerel (MBq) prior PSMA-PET scans” NCT05849298 ↗ |